DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06254261

RecruitingPhase 2

A Study of RAY1225 in Participants With Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Obesity

Asset

RAY1225

Subcutaneous · GLP-1 / GIP dual

Listed sites

1

Recruiting sites

1

Enrollment

270

estimated

Study population

Obesity / overweight

Key I/E criteria

•BMI ≥28•HbA1c 5.7-6.5%

Primary endpoint

•Body Weight

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06254261
Org study IDRAY1225-23-02

Timeline

Milestones

Study first posted2024-02-12actual
Study start2024-02-21actual
Last update posted2025-03-19actual
Primary completion2025-12-20estimated
Study completion2025-12-20estimated

Assets

Investigational agents

RAY1225

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Have a body mass index (BMI) of ≥28 kilogram per square meter (kg/m²) or ≥24 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, fatty liver disease,or HbA1c ≥5.7% and < 6.5%;

2. Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.

Exclusion criteria

1. Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity

2. with a history of diabetes or hypoglycemia;

3. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator.

4. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)

5. allergic constitution;

6. not suitable for subcutaneous injection.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

5 endpoints
Primary/protocol endpoint

Change From Baseline in Body Weight

Time frame:Baseline,Week26

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥10% Body Weight Reduction

Time frame:Baseline,Week26

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥15% Body Weight Reduction

Time frame:Baseline,Week26

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥5% Body Weight Reduction

Time frame:Baseline,Week26

threshold achievement, improvement

Secondary/protocol endpoint

Change from Baseline in Waist Circumference in Centimeter

Time frame:Baseline,Week26

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.